Richard Aldrich Sells 30,000 Shares of Concert Pharmaceuticals Inc (CNCE) Stock

Concert Pharmaceuticals Inc (NASDAQ:CNCE) Director Richard Aldrich sold 30,000 shares of the company’s stock in a transaction on Friday, January 19th. The shares were sold at an average price of $19.35, for a total transaction of $580,500.00. Following the sale, the director now owns 286,975 shares of the company’s stock, valued at approximately $5,552,966.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Richard Aldrich also recently made the following trade(s):

  • On Tuesday, January 16th, Richard Aldrich sold 31,236 shares of Concert Pharmaceuticals stock. The shares were sold at an average price of $19.14, for a total transaction of $597,857.04.

Concert Pharmaceuticals Inc (NASDAQ CNCE) traded down $0.10 on Friday, hitting $19.61. 519,161 shares of the company were exchanged, compared to its average volume of 726,546. Concert Pharmaceuticals Inc has a 1-year low of $8.61 and a 1-year high of $30.71. The company has a market cap of $446.57, a PE ratio of 5.23 and a beta of 1.67.

Concert Pharmaceuticals (NASDAQ:CNCE) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.16). Concert Pharmaceuticals had a net margin of 62.31% and a negative return on equity of 51.48%. research analysts anticipate that Concert Pharmaceuticals Inc will post 4.1 EPS for the current year.

CNCE has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 24th. BidaskClub upgraded shares of Concert Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 9th. UBS Group set a $34.00 price objective on shares of Concert Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 19th. TheStreet upgraded shares of Concert Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Monday, January 8th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $27.00 price objective on shares of Concert Pharmaceuticals in a research report on Friday, January 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $24.33.

A number of hedge funds have recently added to or reduced their stakes in CNCE. Schwab Charles Investment Management Inc. increased its holdings in Concert Pharmaceuticals by 47.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 32,122 shares of the biotechnology company’s stock worth $449,000 after purchasing an additional 10,400 shares in the last quarter. Rhumbline Advisers increased its holdings in Concert Pharmaceuticals by 8.0% during the 2nd quarter. Rhumbline Advisers now owns 20,253 shares of the biotechnology company’s stock worth $283,000 after purchasing an additional 1,500 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Concert Pharmaceuticals by 1.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 125,996 shares of the biotechnology company’s stock worth $1,757,000 after purchasing an additional 1,852 shares in the last quarter. Alliancebernstein L.P. bought a new position in Concert Pharmaceuticals during the 2nd quarter worth about $174,000. Finally, Teachers Advisors LLC increased its holdings in Concert Pharmaceuticals by 11.1% during the 2nd quarter. Teachers Advisors LLC now owns 34,373 shares of the biotechnology company’s stock worth $480,000 after purchasing an additional 3,446 shares in the last quarter. Hedge funds and other institutional investors own 65.29% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Richard Aldrich Sells 30,000 Shares of Concert Pharmaceuticals Inc (CNCE) Stock” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/01/19/richard-aldrich-sells-30000-shares-of-concert-pharmaceuticals-inc-cnce-stock.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply